Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Octreotide acetate|
|Trade Name||Sandostatin Lar Depot|
Sandostatin Lar Depot (octreotide acetate) mimics the activity of somatostatin, which may control the growth of neuroendocrine tumors (PMID: 26605828). Sandostatin Lar Depot (octreotide acetate) is FDA approved for symptom control in patients with carcinoid tumors and VIPomas (FDA.gov).
|CAS Registry Number||79517-01-4|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Cixutumumab + Everolimus + Octreotide acetate||Cixutumumab Everolimus Octreotide acetate||0||0|
|Debio 4126 + Octreotide acetate||Debio 4126 Octreotide acetate||0||1|
|Everolimus + Octreotide acetate||Everolimus Octreotide acetate||0||1|
|lutetium Lu 177 dotatate + Octreotide acetate||Octreotide acetate lutetium Lu 177 dotatate||0||1|
|Octreotide acetate||Octreotide acetate||0||2|